361 Capital’s Biogen BIIB Stock Holding History

361 Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-4,287	Closed	-$1.29M	–	324
2018 Q4	$1.29M	Sell	4,287 -399	-9%	-$127K	0.26%	186
2018 Q3	$1.66M	Buy	+4,686	New	+$1.61M	0.36%	136
2017 Q2	–	Sell	-11,528	Closed	-$3.15M	–	166
2017 Q1	$3.15M	Buy	11,528 +105	+0.9%	+$29.7K	0.67%	62
2016 Q4	$3.24M	Buy	11,423 +11,357	+17,208%	+$3.37M	0.77%	63
2016 Q3	$21K	Buy	+66	New	+$19.5K	0.19%	52

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

361 Capital's BIIB Position: Q1 2019 in Review

361 Capital sold out of Biogen (BIIB) in Q1 2019, closing a stake of 4,287 shares — an estimated $1.29M sold.

361 Capital first reported a position in BIIB in Q3 2016 and held it in 5 quarters. The position peaked at $3.24M in Q4 2016. 1,084 funds tracked by Wall St. Rank hold BIIB as of Q1 2019.

361 Capital reported no remaining Biogen position as of Q1 2019 after selling out during the quarter.
361 Capital sold 4,287 Biogen shares in Q1 2019, an estimated $1.29M.
361 Capital first reported a position in Biogen in Q3 2016 and held it in 5 quarters.
361 Capital's Biogen position peaked at $3.24M in Q4 2016.
1,084 funds tracked by Wall St. Rank held Biogen as of Q1 2019.

Based on 361 Capital's 13F filing for Q1 2019, filed 7 May 2019.